Timothy J. LaBua

Associate Attorney

Skadden, Arps, Slate, Meagher & Flom LLP

Associate Attorney

Wilmer Cutler Pickering Hale & Dorr LLP

• Investment & Operations Counsel at prominent value-focused hedge fund

• 5AM Ventures and MPM Capital in their purchase of preferred equity in Entrada Therapeutics, Inc.
• FOG Pharmaceuticals, Inc. in its Series C Financing
• GV in its purchase of preferred equity in Hyperfine Research, Inc.
• PIC Therapeutics, Inc. in its Series Seed Financing
• 5AM Ventures in its purchase of preferred equity in Scientist.com
• Kanyos Bio, Inc. in its acquisition by Anokion SA
• Massachusetts Eye and Ear in its subscription for equity in Affinia Therapeutics, Inc.
• 6Dimensions Capital in its purchase of preferred equity in Halda Therapeutics, Inc.
• Siamab Therapeutics, Inc. in its acquisition by a publicly listed acquiror
• HotSpot Therapeutics, Inc. in its acquisition of Macroceutics, Inc.
• 5AM Ventures in its purchase of preferred equity in VOR Biopharma
• Kantum Pharma, Inc. in its convertible debt offering
• Tides Medical LLC in its initial equity financing
• 6Dimensions Capital in its purchase of preferred equity in HiberCell
• 5AM Ventures in its purchase of preferred equity in Nido Biosciences
• GV in its purchase of preferred equity in Endcadia, Inc.
• Apic Bio, Inc. in its Series A Financing
• XyloCor Therapeutics, Inc. in its Series A Financing
• Venn Biosciences Corporation in its Series A Financing
• Guardian Therapeutics, LLC in its acquisition of Band Therapeutics, LLC
• Kantum Diagnostics, Inc. in its convertible debt financing
• Synedgen, Inc. in its out-license of IP and sale of assets to Synspira, LLC
• Synspira, LLC in its equity/debt financing and research funding from The Cystic Fibrosis Foundation Trust
• Profit Tools, Inc. in its sale of certain assets to Valsoft Corporation
• FOG Pharmaceuticals, Inc. in its Series B Financing
• LifeMine Therapeutics, Inc. in its Series A Financing
• Renoviso, Inc. in its Series A-1 Financing
• Lundbeckfond Ventures in its sale of certain royalty rights
• Bio-Pharm, Inc. in its acquisition by Torrent Pharmaceuticals Ltd.
• Hexcel Corporation in its acquisition of the aerospace and defense business of Oxford Performance Materials, Inc.
• Alnylam Pharmaceuticals, Inc. in its strategic collaboration with Vir Biotechnology to develop RNAi therapeutics for infectious diseases
• .406 Ventures, LLC in its purchase of preferred equity in Trilio Data, Inc.
• .406 Ventures, LLC as selling shareholder in the acquisition of Jisto, Inc. by Trilio Data, Inc.
• VivoPharm Pty. Ltd. in its acquisition by Cancer Genetics, Inc.
• GO Therapeutics, Inc. in its Series A-1 Financing
• Lysosomal Therapeutics, Inc. in its exclusive option arrangement with Allergan plc
• PTC Therapeutics, Inc. in its Senior Secured Term Loan Facility
• Hexcel Corporation in its strategic investment in Carbon Conversions, Inc.